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Abstract
Background: Visceral adiposity index (VAI) has recently been developed based on waist circumference, body mass
index (BMI), triglycerides (TGs), and high-density lipoprotein cholesterol (HDL-C). We examined predictive
performances for incident diabetes of the VAI per se and as compared to the metabolic syndrome (MetS) and
waist-to-height-ratio (WHtR).
Methods: Participants free of diabetes at baseline with at least one follow-up examination (5,964) were included
for the current study. Weibull regression models were developed for interval-censored survival data. Absolute and
relative integrated discriminatory improvement index (IDI) and cut-point-based and cut-point-free net
reclassification improvement index (NRI) were used as measures of predictive ability for incident diabetes added by
VAI, as compared to the MetS and WHtR.
Results: The annual incidence rate of diabetes was 0.85 per 1000 person. Mean VAI was 3.06 (95%CIs 2.99-3.13).
Diabetes risk factors levels increased in stepwise fashion across VAI quintiles. Risk gradient between the highest
and lowest quintile of VAI was 4.5 (95%CIs 3.0-6.9). VAI significantly improved predictive ability of the MetS. The
relative IDI and cut-point free NRI for predictive ability added to MetS by VAI were 30.3% (95%CIs 18.8-41.8%) and
30.7% (95%CIs 20.8-40.7%), respectively. WHtR, outperformed VAI with cut-point-free NRI of 24.6% (95%CIs
14.1-35.2%).
Conclusions: In conclusion, although VAI could be a prognostic tool for incident diabetes events, gathering
information on its components (WC, BMI, TGs, and HDL-C) is unlikely to improve the prediction ability beyond
what could be achieved by the simply assessable and commonly available information on WHtR.
Background
The prevalence of Type 2 diabetes (hereafter diabetes) is
undergoing a rapid progression [1], largely as a conse-
quence of the epidemic proportions reached by obesity
in various populations of the world [2]. “However, phy-
sicians have been puzzled by the heterogeneity of obe-
sity as not every obese patient develops chronic
complications [3].” In this regard, visceral adiposity, has
been found to be associated with an increased risk of a
cluster of diabetogenic, atherogenic, prothrombotic and
inflammatory metabolic abnormalities increasing the
risk of diabetes [3]. Visceral obesity [4] is associated
with deterioration of insulin sensitivity [5], increased
risk of developing diabetes, and “high-triglycerides
(TGs)/low high-density lipoprotein cholesterol (HDL-C)
dyslipidemia [6].” The identification of a routinely
applicable indicator for the evaluation of visceral adipose
function, with higher sensitivity and specificity than clas-
sical parameters such as waist circumference (WC),
body mass index (BMI), and lipids, could be useful for
cardiometabolic risk assessment. On the other hand,
Reaven proposed that insulin resistance was a funda-
mental “disorder” associated with metabolic abnormal-
ities mentioned above [7]. As most physicians cannot
measure indices of insulin sensitivity in the context of
their clinical practice, some organizations [8-15] have
proposed to use simple clinical parameters to find
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who would also show the diabetogenic abnormalities:
giving birth to the “metabolic syndrome (MetS)”.I ti s
not the scope birth of this study to deal with the ques-
tion of whether or not it is insulin resistance or visceral
obesity/ectopic fat which is the key primary culprit for
the MetS. However, the fact that the variables proposed
in definitions of MetS are not used as continuous vari-
ables in a proper risk calculator likely makes these
screening tools less than perfect for the optimal diagno-
sis of the cardiometabolic risk [16]. Additional work is
needed to clarify this issue and a global MetS calculator
with variables treated as continuous variables would
help address this problem [17]. Amato et al [6] has
recently developed a novel sex-specific index based on
W C ,B M I ,t r i g l y c e r i d e s( T G s ) ,a n dH D La n dt e r m e di t
visceral adiposity index (VAI), and observed that VAI is
highly correlated with visceral adiposity measured by
magnetic resonance imaging (the gold standard
method). Less is known about predictive ability of VAI
for visceral-adiposity-related cardiometabolic risk.
Neither is known about a VAI level corresponding to
the threshold of such risks.
Visceral adiposity is so strongly linked to the type 2
diabetes, that some experts have recently suggested the
new term called “Diabesity” [18]. Therefore, using a
large population-based prospective study we examined:
first, if VAI could provide as much information as is
expected to be obtained from original modeling of its
components. Second, if VAI could outperform MetS in
predicting incident diabetes. Third, if VAI could add to
the predictive ability of simple anthropometric measures
of adiposity, among which waist-to-height-ratio (WHtR)
has been observed to be the best predictor of incident
diabetes [19] and its complications [20]. Finally, we
determined the VAI level corresponding to the thresh-
old of risk for incident diabetes.
Methods and materials
Study population
The Tehran Lipid and Glucose Study (TLGS) is an
ongoing prospective population based study performed on
a representative sample of the Tehran population, with the
aim of determining the prevalence of non-communicable
disease (NCD) risk factors and developing a healthy life-
style to improve them [11,12]. The baseline survey was
performed from February 1999 to July 2001(phase 1) and
4751 families, which included more than 15,000 residents
o fd i s t r i c t - 1 3o fT e h r a na g e d≥3 years, were selected by
cluster random-sampling method. After this cross-sec-
tional phase, participants entered into a cohort and a pro-
spective interventional study (lifestyle modification
education). The current study used the data from 10,368
individuals aging 20 years or older at baseline examination.
After exclusion of participants with prevalent diabetes (n =
1,164), and those with missing data regarding fasting and 2
hour post challenge plasma glucose (2h-PCPG) (n = 884),
8,320 non-diabetic participants remained eligible to be
reexamined in two consecutive phases, one from Septem-
ber 2001 to August 2005 (phase 2) and the other from
April 2005 to March 2008 (phase3). The same standard
approach is followed to collect information across conse-
cutive examinations of the TLGS follow up study. Partici-
pants with at least one follow-up examination (5,964) were
included for the current study.
Clinical and laboratory measurements
A trained interviewer collected information using a pre-
tested questionnaire. The information obtained included
demographic data, family history of diabetes, and drug
use. Weight was measured, with participants minimally
clothed without shoes, using digital scales (Seca 707:
range 0.1-150 kg) and recorded to the nearest 100 g.
Height was measured in a standing position without
shoes, using tape meter while shoulders were in a nor-
mal alignment. Waist circumference (WC) was mea-
sured at the umbilical level. Waist-to-height ratio
(WHpR) was calculated by dividing WC by hip circum-
ference and waist-to-height ratio (WHtR) by dividing
WC by height. Two measurements of systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were
taken using a standardized mercury sphygmomanometer
on the right arm, after a 15 minute rest in a sitting posi-
tion; mean of the two measurements was considered as
participants’ blood pressure [12]. A blood sample was
drawn between 7:00 and 9:00 AM from all study partici-
pants, after 12 to 14 hours overnight fasting. All the
blood analyses were undertaken at the TLGS research
laboratory on the day of blood collection. Plasma glu-
cose was measured using an enzymatic colorimetric
method with glucose oxidase. Fasting plasma glucose
(FPG) measurement was performed for all participants,
and the standard 2h-PCPG test for those not on glu-
cose-lowering drugs. Total cholesterol (TC) was assayed,
using the enzymatic colorimetric method with choles-
terol esterase and cholesterol oxidase. High-density lipo-
protein cholesterol (HDL-C) was measured after
precipitation of the apolipoprotein B containing lipopro-
teins with phosphotungistic acid. Triglycerides (TGs)
were assayed using enzymatic colorimetric assay with
glycerol phosphate oxidase. Analyses were performed
using Pars Azmon kits (Pars Azmon Inc., Tehran, Iran)
and a Selectra 2 auto-analyzer (Vital Scientific, Spanke-
ren, Netherlands). All samples were analyzed when
internal quality control met the acceptable criteria. The
intra and inter-assay coefficients of variation were both
<2.2% for plasma glucose, and 0.5 and 2% for TC,
respectively [21].
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MetS was defined using the updated harmonized defini-
tion [8]. We used WC cutoff points known to be appro-
priate for Persian men and women [22]. Therefore,
MetS was ascertained in individuals meeting three or
more of the following criteria. (1) Waist circumference
≥ 94.5 cm. 8 (2) HDL-C <1.04 mmol.l
-1 (40 mg.dl
-1)i n
men and <1.30 mmol.l
-1 (50 mg.dl
-1) in women. (3) TGs
≥1.7 mmol.l
-1 (150 mg.dl
-1) or specific treatment for this
lipid abnormality. (4) Hypertension defined as SBP ≥130
mmHg or DBP ≥85 mmHg or treatment of previously
diagnosed hypertension. (5) FPG ≥5.5 mmol.l
-1 (100 mg.
dl
-1) or previously diagnosed diabetes. Positive family
h i s t o r yo fd i a b e t e sw a sd e f i n e da sh a v i n ga tl e a s to n e
parent or sibling with diabetes. Participants were classi-
fied as having diabetes at the baseline or during follow-
up if they met at least one of these criteria: FPG ≥7
mmol.l-1, or 2h-PCPG≥11.1 mmol.l
-1 or taking anti-dia-
betic medication [23]. Following Amato et al [6] we
defined VAI as:
Males =

WC
39.68 + (1.88 × BMI)

×

TGs
1.03

×

1.31
HDL - C

Females =

WC
36.58 + (1.89 × BMI)

×

TGs
0.81

×

1.52
HDL - C

assuming VAI = 1 in healthy non-obese subjects with
normal adipose distribution and normal TG and HDL
levels.
Statistics
Findings on covariate variables are expressed as means
(SD) or percentages for continuously distributed and
categorical variables, respectively. We tested for trends
across VAI quartiles by using the median in each quar-
tile as a predictor. The General Linear Model was devel-
oped to examine significance of trends in potential
predictors of diabetes across VAI quintiles. The Mantel-
Cox method used for estimating incident rates and the
Log-Rank test was performed to examine the signifi-
cance of trends across VAI quintiles with survival time
being the time from start of the follow-up period to the
mid-point between the examination date at which an
individual was seen free of diabetes and the examination
date at which the diabetes was diagnosed (failure). The
censoring time of an individual was the time from entry
into the study to loss to follow-up or the end of the
study, whichever happened first.
In the analysis of incident diabetes, VAI was assessed
using accelerated failure time (AFT) survival regression
analyses. Weibull proportional hazard regression models
were developed for interval-censored survival data, since
the precise date of developing diabetes could not be
determined and the TLGS records provided only an
interval for each diabetes diagnosis. We chose our can-
didate covariates among the ones that were validated
from the literature and new ones that are suspected of
playing important roles in the development of diabetes
[19,24,25]. As such, our covariate selection can be
regarded as being guided by scientific as well as numeric
evidence. The following variables served as standard
candidate risk factors: age, sex, BMI, WC, SBP, DBP,
family history of diabetes, TGs, HDL-C, and glucose
levels [24]. We followed statistical guidelines with
respect to the significance of association of a variable
with incident diabetes but also considered scientific and
qualitative judgment as well. For example we did not
adjust for WC, TGs, and HDL-C which are components
of the VAI and therefore not appropriate to be adjusted
for in prediction models already incorporating VAI.
Among anthropometric measures of adiposity, WHtR
was previously observed to be the best predictor of inci-
dent diabetes [19] and its complications [20]. We there-
fore, examined if VAI could add to the predictive ability
for incident diabetes of WHtR. Also, we compared the
predictability for incident diabetes of VAI with MetS.
Assessment of Model Performance
Bias-variance tradeoff
Models with many covariates have low bias but high
variance; models with few covariates have high bias but
low variance. The best predictions come from balancing
these two extremes. This is called the bias-variance tra-
deoff. The problem of deciding which variables to
include in the regression model to achieve a good trade-
off is called model selection or variable selection. Akaike
information criterion (AIC) and the Bayesian informa-
tion criterion (BIC) were used as measures of bias-var-
iance tradeoff, indicating whether the addition of new
covariate(s) to a base model provides better risk predic-
tion than the base model alone, provided that all of the
same individuals are being assessed by both models
[26,27]. Difference in AICs (ΔAIC) >10 was considered
to be statistically significant.
Discrimination
In the survival analysis, discrimination, which is quanti-
fied by the Harrell’s C statistic, by is equivalent to the
area under a receiver operating characteristic (ROC)
curve for binary dependent variables [28]. The Harrell’s
C statistic measures the probability that a randomly
selected person who developed an event, at the certain
specific time has a higher risk score than a randomly
selected person who did not develop an event during
the same specific follow-up interval [29,30]. For C-statis-
tics bias-corrected 95%CIs were estimated with Boot-
strap resampling.
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Calibration “describes how closely predicted probabil-
ities agree numerically with actual outcomes (do close
to x of 100 participants with a risk prediction of x%
have the outcome? For example, if we predicted a
10% risk of incident diabetes for a participant, the
observed incidence of diabetes should be approxi-
mately 10 of 100 participants with such a prediction)
[31-33]“. For this purpose, the TLGS participants
were divided into deciles of 6-year incident diabetes
risk predicted by each model. We used the Kaplan-
Meier estimator to obtain the observed incidence of
diabetes, which was then compared with the incident
diabetes risk predicted by the model. The predicted
and actual risks in each decile were compared, and
the difference was assessed by Nam-D’Agostino test,
c
2 which is a modified version of the Hosmer-Leme-
show c
2 test for survival regression models. Values
exceeding 20 indicate significant lack of calibration
(P<0.01) [31].
Added predictive capacity-integrated discrimination index
(IDI) and net reclassification index (NRI)
Absolute and relative IDI and cut-point-based and cut-
point-free NRI were used as measures of predictive abil-
ity for incident diabetes added by VAI [34]. Bootstrap-
ping method was implemented in order to obtain bias-
corrected 95% confidence intervals (95% CIs).
Non-linear contribution of the VAI to the risk of incident
diabetes
Instead of using arbitrary predetermined cut-points, we
used multivariate restricted cubic splines, with 4 knots
defined at, 5
th,2 5
th,7 5
th,a n d9 5
th percentiles [27].
Splines functions, as phrased by Harrell, are “piecewise
polynomials within the intervals of a variable that are
connected across different intervals of that variable
[27].” This flexible approach guarantees that both non-
linear and linear trends are well captured [27]. In vari-
able selection, we dropped a variable if its removal
causes a non-significant increase in deviance. We set the
significance levels for covariate selection by backward
elimination at 0.1. For VAI, however, we set the signifi-
cance level at unity, forcing it into the model, leaving
others to be selected or not.
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of human
volunteers were followed during this research. Informed
written consent was obtained from all participants and
the Ethical Committee of Research Institute for Endo-
crine Sciences approved this study. We set the statistical
significance level at a two-tailed type I error of 0.05. All
statistical analyses were performed using STATA ver-
sion 11 (STATA, College Station, Texas USA) and SAS
9.0 (SAS Institute, Cary, NC, USA).
Results
During a median 6-year follow up of 5,964 (3,440
women) participants of the TLGS, contributing to
435,299 person-year follow up, we documented 369
cases of incident diabetes. The annual incidence rate of
diabetes was 0.85 per 1000 person. Mean VAI was 3.06
(95% CIs 2.99-3.13). Diabetes risk factors levels
increased in stepwise fashion across VAI quintiles
(Table 1).
Figure 1 depicts the diabetes-free survivor function for
each of the VAI quintile (Log-Rank c
2 = 108.7, P for
equality of survivor functions < 0.0001). The age-
adjusted annual incidence rate (95% CIs) per 1000 per-
son were 54.1 (52.3-55.8), 58.1 (56.5-59.7), 64.5 (62.7-
66.2), 65.5 (63.8-67.1), and 66.7 (65.1-68.3) for the first
through fifth quintiles of VAI.
Age-adjusted HRs for incident diabetes increased, in
stepwise fashion, with increasing VAI quintiles (P for
trend <0.001). Age-adjusted hazard ratios of the second
through fifth VAI quintiles for incident diabetes as com-
pared to the first quintile were 1.5 (95% CIs 0.9-2.5), 2.4
(95% CIs 1.5-3.8), 3.3 (95% CIs 2.2-5.1), 4.5 (95% CIs
3.0-6.9), respectively. Risk gradient between the highest
and lowest quintile of VAI was 4.5 (95% CIs 3.0-6.9).
Table 2, 3, 4, and 5 present the predictive perfor-
mances of a combination of VAI components, VAI per
se, MetS, and WHtR. Discrimination capacity of the
VAI-based model (Harrell’s C 0.848, 95% CIs 0.827-
0.870) was higher than that of the MetS-based model
(Harrell’s C 0.748, 95% CIs 0.723-0.771) and similar to
the components-based model (Harrell’s C 0.853, 95%
CIs 0.832-0.873). When we examined WHtR with the
same level of adjustments, the Harrell’s C was 0.851
(95% CI 0.830-0.872).
As compared to the model incorporating VAI, bias-
variance tradeoff was better when WHtR were intro-
duced to the regression model (ΔAIC = 16, <0.001). The
model based on WHtR provided the best BIC (2707).
As shown in Table 6, VAI significantly improved pre-
dictive ability of the MetS. The relative IDI and cut-
point free NRI for predictive ability added to MetS by
VAI were 30.3% (95% CIs 18.8-41.8%) and 30.7% (95%
CIs 20.8-40.7%), respectively. WHtR, outperformed VAI
with cut-point-free NRI of 24.6% (95% CIs 14.1-35.2%).
Figure 2 depicts the non-linear association of the VAI
with risk of incident diabetes. The risk started at VAI of
2 units. Below this threshold decreasing VAI was asso-
ciated with steeper decrease in the risk of incident
diabetes.
Neither male sex (HR 0.85, 95% CIs 0.63-1.13; P =
0.257) nor lifestyle modification measure were associated
with risk of incident diabetes (HR 0.86, 95%CIs 0.64-
1.16; P = 0.327). Nonetheless, as ancillary analyses, we
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assigned vs. those not assigned to the life style modifica-
tion intervention measures as well as among men vs.
among women. The analyses results were robust in sub-
group analyses and the results remained essentially
unchanged in terms of magnitude and significance. For
example the HR for incident diabetes of VAI among
participants assigned and not assigned to the life style
modification intervention measures were 1.03 (95% CIs
1.01-1.06) and 1.04 (95% CIs 1.01-1.07) (P for interac-
tion = 0.940). The HR for both men and women was
1.04 (95%CIs 1.01-1.06) (P for interaction = 0.453).
Therefore, to capture full power and information along
with parsimony, we did not split the original sample for
final presentation.
Discussion
This is the first demonstration of the predictive perfor-
mance of VAI for predicting risk of the diabetes: the
most strongly related risk to the visceral fat [35]. We
observed that VAI statistically significantly and clinically
meaningfully added to the predictive ability of the MetS.
VAI, however, did not grant any predictive information
beyond what could be achieved by using WHtR.
Our finding of interest was that whereas WC, BMI,
TGs, and HDL-C were not independently associated to
risk of incident diabetes, VAI independent of age, family
history of diabetes, smoking, FPG, and 2h-PCPG pre-
dicted. Amato et al postulated that VAI includes both
physical and metabolic parameters and perhaps indir-
ectly reflects other non-classical risk factors, such as
altered production of adipocytokines, increased lipolysis,
and plasma free fatty acids, which are not signified by
BMI, WC, TGs, and HDL-C separately [6]. Therefore,
VAI might be a valuable index of both fat distribution
and function.
It is well-documented that obesity is associated with
diabetes [35]. However, obesity is remarkably heteroge-
neous as some obese patients never develop diabetes
[36]. With such a remarkable heterogeneity of obesity in
Table 1 Baseline diabetes risk factor levels
a across VAI quintiles
Variable Quintile1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for
trend
0.21-1.29 unit 1.29-193 unit 1.93-283 unit 2.83-4.30 unit 4.30-41.5 unit
Age (years) 37.43 (14.05) 40.13 (13.37) 43.26 (13.78) 44.26 (12.59) 44.98 (12.31) <0.001
SBP (mm Hg) 112.81 (15.99) 115.54 (16.86) 118.59 (17.30) 121.83 (18.05) 122.68 (17.80) <0.001
DBP (mm Hg) 73.33 (10.00) 75.89 (10.14) 77.84 (10.10) 79.79 (10.22) 80.70 (10.32) <0.001
DM-FHx 0.22 (0.42) 0.25 (0.43) 0.27 (0.44) 0.29 (0.45) 0.29 (0.46) <0.001
LPA (times/week)
≥3 313 (26.35) 315 (26.54) 302 (25.42) 265 (22.33) 270 (22.75)
<3 177 (14.9) 149 (12.55) 155 (13.05) 160 (13.48) 161 (13.56) 0.004
Never 698 (58.75) 723 (60.91) 731 (61.53) 762 (64.2) 756 (63.69)
Current smoker 140 (11.8) 131 (11.06) 146 (12.29) 158 (13.33) 178 (15.01) 0.003
Waist (cm) 79.33 (10.65) 84.82 (11.18) 88.56 (10.67) 91.68 (10.57) 94.48 (9.69) <0.001
BMI (Kg.m
-2) 24.00 (4.23) 25.96 (4.37) 27.07 (4.13) 28.24 (4.33) 28.91 (4.02) <0.001
HDL-C(mmol.l
-1) 1.35 (0.28) 1.18 (0.23) 1.08 (0.22) 1.00 (0.20) 0.86 (0.19) <0.001
WHpR (%) 82.02 (8.12) 84.82 (8.60) 87.61 (8.32) 89.14 (7.84) 90.98 (7.39) <0.001
WHtR (%) 48.65 (6.96) 52.44 (7.50) 54.64 (6.98) 56.76 (7.13) 58.62 (6.66) <0.001
TGs
b (mmol.l
-1) 0.79 (0.78-0.80) 1.18 (1.16-1.19) 1.58 (1.57-1.60) 2.12 (2.09-2.14) 3.29 (3.23-3.36) <0.001
FPG (mmol.l
-1) 4.87 (0.49) 4.90 (0.51) 4.99 (0.51) 5.06 (0.55) 5.14 (0.58) <0.001
PCPG (mmol.l
-1) 5.31 (1.47) 5.60 (1.47) 5.93 (1.57) 6.23 (1.64) 6.57 (1.69) <0.001
BMI, body mass index; DBP, diastolic blood pressure; DM FHx, family history of diabetes; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol;
PCPG, 2-hour post-challenge plasma glucose; SBP, systolic blood pressure; TGs, triglycerides; VAI, visceral adiposity index; WHpR, waist-to-hip ratio; WHtR, waist-
to-height ratio.
a. Variables are presented as mean (SD).
b. For TGs geometric mean (95% CIs) has been reported since the distribution was highly skewed.
Figure 1 Kaplan-Meier survival curves across quintiles of the
VAI. VAI, visceral adiposity index.
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as the waist circumference (WC) is clinically relevant
[35,37]. Nevertheless, WC alone does not help distin-
guishing between subcutaneous and visceral fat mass [38];
the latter to play a decisive role in the genesis of cardiovas-
cular sequelae [3,39,40]. With the introduction of the
MetS, the abdominal obesity was recognized as a clinically
measurable (although imperfect) entity [35,41-43]. On the
other hand, as an alternative to MetS, a more fundamental
syndromic concept has been introduced. It might be
defined by the limited capacity of the human body to buf-
fer and dispose of lipid fuels. During periods of lipid
excess, along with expansion of visceral adipocytes, the
blood concentrations of certain lipids would become
chronically elevated. This state, referred to as “lipid over-
accumulation” [44], could lead to ectopic deposition of
lipids in non-adipose tissues, where insulin resistance and
other metabolic dysfunctions would arise [45-47]. Lipid
accumulation product (LAP), based on a combination of
WC and TG has recently been introduced by Kahn et al
[45] and shown to predict incident diabetes [48], CVD
[49], and all-cause mortality [50]. We have previously
shown that if LAP is to be used for predicting diabetes, it
might not be superior to WHtR [48]. Herein, we showed
that, although far superior to MetS, VAI is not superior to
WHtR for predicting diabetes, underscoring the predictive
capacity for incident diabetes of the WHtR.
In estimating model parameters, while decreasing bias, it
is possible to increase the variance, by adding parameters
Table 3 Predicting diabetes based on VAI
HR SE Wald
statistic
P
value
95% CIs
Lower Upper
VAI-based model
Age (years) 1.00 0.00 0.17 0.868 0.99 1.01
Family history of
diabetes
1.67 0.18 4.79 0.000 1.36 2.07
SBP (mm Hg) 1.01 0.00 1.69 0.091 1.00 1.02
DBP (mm Hg) 1.01 0.01 0.82 0.411 0.99 1.02
Current smoker 1.16 0.19 0.89 0.373 0.84 1.60
Leisure time physical
activity
0.93 0.06 -1.17 0.241 0.82 1.05
FPG (mmol.l
-1) 3.75 0.36 13.83 0.000 3.11 4.53
PCPG (mmol.l
-1) 1.50 0.05 12.16 0.000 1.41 1.60
VAI (unit) 1.04 0.01 3.26 0.001 1.01 1.06
Nam-D’Agostino X
2 (P for
lack of fit)
17.1 (0.048)
Harrell’s C (95% CIs) 0.849 (0.828-0.871)
Akaike information
criterion
2650
Bayesian information
criterion
2723
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma
glucose; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; PCPG, 2-
hour post-challenge plasma glucose; SBP, systolic blood pressure; TGs,
triglycerides; VAI, visceral adiposity index.
Table 4 Predicting diabetes based on MetS
HR SE Wald
statistic
P
value
95% CIs
Lower Upper
MetS-based model
Age (years) 1.00 0.01 0.93 0.354 0.99 1.01
Family history of
diabetes
1.61 0.17 4.36 0.000 1.30 1.99
Current smoker 1.38 0.23 1.94 0.053 1.00 1.90
Leisure time physical
activity
0.91 0.06 -1.58 0.114 0.80 1.02
BMI (kg.m
-2) 1.05 0.01 4.07 0.000 1.03 1.07
PCPG (mmol.l
-1) 1.73 0.06 17.20 0.000 1.63 1.84
MetS 1.96 0.26 5.04 0.000 1.51 2.54
Nam-D’Agostino X
2 (P for
lack of fit)
8.6 (0.479)
Harrell’s C (95% CIs) 0.820 (0.797-0.843)
Akaike information
criterion
2812
Bayesian information
criterion
2872
BMI, body mass index; HR, hazard ratio; MetS, metabolic syndrome; PCPG,
2-hour post-challenge plasma glucose.
Table 2 Predicting diabetes based on VAI components
HR SE Wald
statistic
P
value
95% CIs
Lower Upper
VAI components-based
model
Age (years) 1.00 0.01 -0.20 0.841 0.99 1.01
Family history of
diabetes
1.62 0.17 4.44 0.000 1.31 2.00
SBP (mm Hg) 1.01 0.00 1.62 0.106 1.00 1.01
DBP (mm Hg) 1.00 0.01 -0.02 0.988 0.99 1.01
Current smoker 1.08 0.18 0.45 0.656 0.77 1.50
Leisure time physical
activity
0.92 0.06 -1.40 0.161 0.81 1.04
FPG (mmol.l
-1) 3.56 0.34 13.20 0.000 2.95 4.29
PCPG (mmol.l
-1) 1.49 0.05 11.83 0.000 1.39 1.59
Waist circumference
(cm)
1.02 0.01 1.69 0.092 1.00 1.03
BMI (kg.m
-2) 1.02 0.02 0.93 0.350 0.98 1.06
Log-TGs (mmol.l
-1) 1.17 0.13 1.40 0.161 0.94 1.45
HDL-C (mmol.l
-1) 0.75 0.17 -1.26 0.209 0.47 1.18
Nam-D’Agostino X
2 (P for
lack of fit)
28.3 (0.001)
Harrell’s C (95% CIs) 0.848 (0.827-0.869)
Akaike information
criterion
2632
Bayesian information
criterion
2726
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma
glucose; HDL-C, high-density lipoprotein cholesterol; PCPG, 2-hour post-
challenge plasma glucose; SBP, systolic blood pressure; TGs, triglycerides.
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Page 6 of 9[27]. From statistical point of view, thus, it is potentially
useful to have an index like VAI representing several para-
meters (its components). We observed, however, that the
VAI failed to flourish this potential.
Clinical importance of visceral adiposity lies in its asso-
ciation with health risks like diabetes. Therefore, from
clinical point-of-view, indices developed to measure visc-
eral adiposity should be examined with respect to their
ability to predict risks known to be associated with visc-
eral adiposity [48,49]. Further studies are required to
examine if VAI can improve CVD prediction.
The VAI could be examined with respect to its effects
on some new biomarkers that have recently been shown
to be associated with risk of incident diabetes [51,52].
We, however, did not included biomarkers in our ana-
lyses since VAI is supposed to provide a simple surro-
gate measure of functional and structural adiposity.
Further, the association of new biomarkers with risk of
incident diabetes is still controversial [53,54].
The major strength of our prospective study lies in the
reliable follow up in a well-characterized population-
based sample in which diabetes and its risk factors have
been assessed with standardized measures both at base-
line and follow up, systematically recording all of the
variables required to the define VAI and completeness
of ascertainment and accuracy of classification.
The interpretation of present data needs to be
assessed within the context of the potential limitation of
our study. First, some misclassification of diabetes status
may have occurred due to lacking confirmatory test for
newly diagnosed diabetes. Second, there is an innate
limitation to the concept of MetS, which has different
definitions. We, however, have chosen among different
definitions, the one that has been agreed upon by devel-
opers of different definitions of MetS [8]. Third, we did
not examine if VAI could predict insulin resistance
more accurate than diabetes. There is, however, no
widely accepted method for measuring insulin resistance
to be used in clinical practice. Fourth, VAI could be
examined with respect to its effects on some new bio-
markers that have recently been shown to be associated
with risk of incident diabetes [51,52]. We however, did
not included biomarkers in our analyses since VAI is
supposed to provide a simple proxy measure of func-
tional and structural adiposity. Furthermore, associations
of new biomarkers with risk of incident diabetes are still
controversial [53,54]. Finally, participants assigned to life
Figure 2 Non-linear contribution of the VAI to the risk of
incident diabetes. VAI, visceral adiposity index
Table 6 Added predictive ability conferred by VAI
95% CIs P value
Compared with MetS
Absolute IDI (%) 4.8 3.2 6.5 0.000
Relative IDI (%) 30.3 18.8 41.8 0.000
Cut-point-based NRI
a (%) 13.1 6.7 19.6 0.000
Cut-point-free NRI (%) 30.7 20.8 40.7 0.000
Compared with WHtR
Absolute IDI (%) -0.4 -0.9 0.2 0.229
Relative IDI (%) -1.6 -4.3 1.0 0.230
Cut-point-based NRI
a (%) -4.5 -8.2 -0.8 0.018
Cut-point-free NRI (%) -24.6 -35.2 -14.1 0.000
IDI, integrated discriminatory improvement index; MetS, metabolic syndrome;
NRI, net reclassification improvement index; VAI, visceral adiposity index;
WHtR, waist-to-height ratio.
a. For cut-point based NRI, the cut-points were set at 0, 0.05, 0.1, 0.2, and 1.
Table 5 Predicting diabetes based on WHtR
HR SE Wald
statistic
P
value
95% CIs
Lower Upper
WHtR-based model
Age (years) 1.00 0.01 -0.85 0.398 0.99 1.01
Family history of
diabetes
1.60 0.17 4.35 0.000 1.29 1.98
SBP (mm Hg) 0.92 0.06 -1.37 0.170 0.81 1.04
Current smoker 1.25 0.21 1.38 0.168 0.91 1.73
Leisure time physical
activity
1.01 0.00 1.49 0.138 1.00 1.01
BMI (kg.m
-2) 1.00 0.01 0.35 0.723 0.99 1.02
FPG (mmol.l
-1) 3.64 0.35 13.50 0.000 3.01 4.39
PCPG (mmol.l
-1) 1.49 0.05 11.93 0.000 1.40 1.59
WHtR 1.04 0.01 5.05 0.000 1.02 1.05
Nam-D’Agostino X
2 (P for
lack of fit)
19.9 (0.019)
Harrell’s C (95% CIs) 0.851 (0.830-0.872)
Akaike information
criterion
2634
Bayesian information
criterion
2707
BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density
lipoprotein cholesterol; PCPG, 2-hour post-challenge plasma glucose; SBP,
systolic blood pressure; TGs, triglycerides.
Bozorgmanesh et al. Lipids in Health and Disease 2011, 10:88
http://www.lipidworld.com/content/10/1/88
Page 7 of 9style modification intervention measures might have
changed their lifestyle behaviors, and consequently the
risk of developing diabetes. Life style modification inter-
vention measures, however, were not associated with 6-
year risk of incident diabetes. Therefore, to capture full
power (sample size) and information we did not split
the original sample for final presentation.
In conclusion, although VAI could be a prognostic
tool for incident diabetes events, gathering information
on its components (WC, BMI, TGs, and HDL-C) is
unlikely to improve the prediction ability beyond what
could be achieved by the simply assessable and com-
monly available information on WHtR.
Acknowledgements
This study was supported by grant No. 121 from the National Research
Council of the Islamic Republic of Iran. We express our appreciation to the
participants of district-13 of Tehran for their enthusiastic support in this
study.
Author details
1Prevention of Metabolic Disorders Research Center, Research Institute for
Endocrine Sciences (RIES), Shahid Beheshti University of Medical Sciences,
Tehran, Iran.
2Endocrine Research Center, Research Institute for Endocrine
Sciences (RIES), Shahid Beheshti University (M.C.), Tehran, Iran.
Authors’ contributions
MB designed the study, performed the statistical analysis, interpreted the
analyses and drafted the manuscript. FH interpreted the analyses and
revised the manuscript critically for important intellectual content. FA revised
the manuscript critically for important intellectual content. All authors read
and approved the final manuscript
Competing interests
The authors declare that they have no competing interests.
Received: 15 February 2011 Accepted: 27 May 2011
Published: 27 May 2011
References
1. Harati H, Hadaegh F, Saadat N, Azizi F: Population-based incidence of
Type 2 diabetes and its associated risk factors: results from a six-year
cohort study in Iran. BMC Public Health 2009, 9:186.
2. Bozorgmanesh MR, Hadaegh F, Padyab M, Mehrabi Y, Azizi F: Temporal
changes in anthropometric parameters and lipid profile according to
body mass index among an adult Iranian urban population. Ann Nutr
Metab 2008, 53:13-22.
3. Despres JP: Intra-abdominal obesity: an untreated risk factor for Type 2
diabetes and cardiovascular disease. J Endocrinol Invest 2006, 29:77-82.
4. Pascot A, Lemieux S, Lemieux I, Prud’homme D, Tremblay A, Bouchard C,
Nadeau A, Couillard C, Tchernof A, Bergeron J, Després JP: Age-related
increase in visceral adipose tissue and body fat and the metabolic risk
profile of premenopausal women. Diabetes Care 1999, 22:1471-1478.
5. DeNino WF, Tchernof A, Dionne IJ, Toth MJ, Ades PA, Sites CK,
Poehlman ET: Contribution of Abdominal Adiposity to Age-Related
Differences in Insulin Sensitivity and Plasma Lipids in Healthy Nonobese
Women. Diabetes Care 2001, 24:925-932.
6. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M,
Galluzzo A, Group ftAS: Visceral Adiposity Index. Diabetes Care 2010,
33:920-922.
7. Reaven GM: Banting lecture 1988. Role of insulin resistance in human
disease. Diabetes 1988, 37:1595-1607.
8. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,
Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic
syndrome: a joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association; World Heart
Federation; International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
9. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide
definition. Lancet 2005, 366:1059-1062.
10. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome–a new world-wide
definition. A Consensus Statement from the International Diabetes
Federation. Diabet Med 2006, 23:469-480.
11. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes
mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med
1998, 15:539-553.
12. Grundy SM: Definition of metabolic syndrome: report of the National
Heart, Lung, and Blood Institute/American Heart Association
Conference on scientific issues related to definition. Circulation 2004,
109:433-438.
13. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A:
Executive Summary of the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel
III). Jama 2001, 285:2486-2497.
14. Balkau B, Charles MA: Comment on the provisional report from the WHO
consultation. European Group for the Study of Insulin Resistance (EGIR).
Diabet Med 1999, 16:442-443.
15. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y,
Hellman R, Jellinger PS, Kendall D, Krauss RM, et al: American College of
Endocrinology position statement on the insulin resistance syndrome.
Endocr Pract 2003, 9:237-252.
16. Marquis K, Maltais F, Duguay V, Bezeau AM, LeBlanc P, Jobin J, Poirier P:
The metabolic syndrome in patients with chronic obstructive pulmonary
disease. J Cardiopulm Rehabil 2005, 25:226-232, discussion 233-224.
17. Sattar N: The metabolic syndrome: should current criteria influence
clinical practice? Curr Opin Lipidol 2006, 17:404-411.
18. Kushner RF, Roth JL: Assessment of the obese patient. Endocrinol Metab
Clin North Am 2003, 32:915-933.
19. Bozorgmanesh M, Hadaegh F, Ghaffari S, Harati H, Azizi F: A simple risk
score effectively predicted type 2 diabetes in Iranian adult population:
population-based cohort study. Eur J Public Health 2010.
20. Lamacchia O, Pinnelli S, Camarchio D, Fariello S, Gesualdo L, Stallone G,
Cignarelli M: Waist-to-height ratio is the best anthropometric index in
association with adverse cardiorenal outcomes in type 2 diabetes
mellitus patients. Am J Nephrol 2009, 29:615-619.
21. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M,
Mehrabi Y, Zahedi-Asl S: Prevention of non-communicable disease in a
population in nutrition transition: Tehran Lipid and Glucose Study phase
II. Trials 2009, 10:5.
22. Hadaegh F, Zabetian A, Sarbakhsh P, Khalili D, James WP, Azizi F:
Appropriate cutoff values of anthropometric variables to predict
cardiovascular outcomes: 7.6 years follow-up in an Iranian population.
Int J Obes (Lond) 2009, 33:1437-1445.
23. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J,
Knowler WC, Lebovitz H, Lernmark A, et al: Follow-up report on the
diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
24. American Diabetes Association: Standards of Medical Care in Diabetes –
2010. Diabetes Care 2010, 33:S11-S61.
25. Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR,
Ghanbarian A, Mirmiran P, Azizi F: Reduction in incidence of type 2
diabetes by lifestyle intervention in a middle eastern community. Am J
Prev Med 2010, 38:628-636, e621.
26. Akaike H: A new look at the statistical model identification. IEEE Trans
Automat Contr 1974, AC-19:716-723.
27. Harrell FE: Regression modeling strategies Springer New York; 2001.
28. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver
operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
29. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV,
Go AS, Harrell FE Jr, Hong Y, Howard BV, et al: Criteria for Evaluation of
Novel Markers of Cardiovascular Risk: A Scientific Statement From the
American Heart Association. Circulation 2009, 119:2408-2416.
30. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and
measuring and reducing errors. Stat Med 1996, 15:361-387.
Bozorgmanesh et al. Lipids in Health and Disease 2011, 10:88
http://www.lipidworld.com/content/10/1/88
Page 8 of 931. D’Agostino RB, Nam BH: Evaluation of the performance of survival
analysis models: Discrimination and Calibration measures. In Handbook
of Statistics, Survival Methods. Volume 23. Edited by: Balakrishnan N, Rao CR.
Amsterdam, The Netherlands: Elsevier BV; 2004:1-25.
32. Hosmer DW, Lemeshow S: Applied logistic regression Wiley-Interscience;
2000.
33. Hosmer DW, Lemeshow S, May S: In Applied survival analysis: regression
modeling of time-to-event data.. 2 edition. Edited by: Hoboken, NJ. Wiley-
Interscience; 2008:.
34. Pencina MJ, D’Agostino RB, D’Agostino RB Jr, Vasan RS: Evaluating the
added predictive ability of a new marker: from area under the ROC
curve to reclassification and beyond. Stat Med 2008, 27:157-172,
discussion 207-112.
35. Despres J-P, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodes-
Cabau J, Bertrand OF, Poirier P: Abdominal Obesity and the Metabolic
Syndrome: Contribution to Global Cardiometabolic Risk. Arterioscler
Thromb Vasc Biol 2008, 28:1039-1049.
36. Reaven G, Abbasi F, McLaughlin T: Obesity, Insulin Resistance, and
Cardiovascular Disease. Recent Prog Horm Res 2004, 59:207-223.
37. Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R: Body mass index
and waist circumference independently contribute to the prediction of
nonabdominal, abdominal subcutaneous, and visceral fat. The American
Journal of Clinical Nutrition 2002, 75:683-688.
38. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A,
Nadeau A, Lupien PJ: Waist circumference and abdominal sagittal
diameter: best simple anthropometric indexes of abdominal visceral
adipose tissue accumulation and related cardiovascular risk in men and
women. Am J Cardiol 1994, 73:460-468.
39. Despres JP: Visceral adiposity 2006.
40. Despres JP: Is visceral obesity the cause of the metabolic syndrome? Ann
Med 2006, 38:52-63.
41. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of
metabolic syndrome: Report of the National Heart, Lung, and Blood
Institute/American Heart Association conference on scientific issues
related to definition. Circulation 2004, 109:433-438.
42. Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome.
Nature 2006, 444:881-887.
43. Reaven GM: The individual components of the metabolic syndrome: is
there a raison d’etre? J Am Coll Nutr 2007, 26:191-195.
44. Unger RH: Lipid overload and overflow: metabolic trauma and the
metabolic syndrome. Trends Endocrinol Metab 2003, 14:398-403.
45. Kahn HS: The “lipid accumulation product” performs better than the
body mass index for recognizing cardiovascular risk: a population-based
comparison. BMC Cardiovasc Disord 2005, 5:26.
46. Kahn HS: The lipid accumulation product is better than BMI for
identifying diabetes: a population-based comparison. Diabetes Care 2006,
29:151-153.
47. Kahn HS, Valdez R: Metabolic risks identified by the combination of
enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr
2003, 78:928-934.
48. Bozorgmanesh M, Hadaegh F, Azizi F: Diabetes prediction, lipid
accumulation product, and adiposity measures; 6-year follow-up: Tehran
lipid and glucose study. Lipids Health Dis 2010, 9:45.
49. Bozorgmanesh M, Hadaegh F, Azizi F: Predictive performances of lipid
accumulation product vs. adiposity measures for cardiovascular diseases
and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose
study. Li pids Health Dis 2010, 9:100.
50. Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ: The Lipid
Accumulation Product and All-cause Mortality in Patients at High
Cardiovascular Risk: A PreCIS Database Study. Obesity (Silver Spring) 2009.
51. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T,
Aromaa A, Evans A, Kuulasmaa K, Blankenberg S: Thirty-One Novel
Biomarkers as Predictors for Clinically Incident Diabetes. PLoS ONE 2010,
5:e10100.
52. Kolberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E,
Rowe MW, Urdea MS, Xu XM, Hansen T, et al: Development of a type 2
diabetes risk model from a panel of serum biomarkers from the Inter99
cohort. Diabetes Care 2009, 32:1207-1212.
53. Schulze MB, Weikert C, Pischon T, Bergmann MM, Al-Hasani H, Schleicher E,
Fritsche A, H¤ring H-U, Boeing H, Joost H-G: Use of Multiple Metabolic
and Genetic Markers to Improve the Prediction of Type 2 Diabetes: the
EPIC-Potsdam Study. Diabetes Care 2009, 32:2116-2119.
54. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr:
Prediction of incident diabetes mellitus in middle-aged adults: the
Framingham Offspring Study. Arch Intern Med 2007, 167:1068-1074.
doi:10.1186/1476-511X-10-88
Cite this article as: Bozorgmanesh et al.: Predictive performance of the
visceral adiposity index for a visceral adiposity-related risk:
Type 2 Diabetes. Lipids in Health and Disease 2011 10:88.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bozorgmanesh et al. Lipids in Health and Disease 2011, 10:88
http://www.lipidworld.com/content/10/1/88
Page 9 of 9